Clinical significance of signal pattern of high-risk human papillomavirus using a novel fluorescence in situ hybridization assay in cervical cytology  by Ho, C.-M. et al.
Clinical signiﬁcance of signal pattern of high-risk human papillomavirus
using a novel ﬂuorescence in situ hybridization assay in cervical cytology
C.-M. Ho1–3, B.-H. Lee4, S.-F. Chang5, T.-Y. Chien1, S.-H. Huang6, C.-C. Yan4 and W.-F. Cheng7,8
1) Department of Obstetrics and Gynecology, Gynecologic Cancer Center, Cathay General Hospital, Taipei, 2) School of Medicine, Fu Jen Catholic University,
Hsinchuang, Taipei Hsien, 3) School of Medicine, Taipei Medical University, Taipei, 4) King Car Food Industrial Co, Ltd, Yuan Shan Research Institute, Elan,
5) Graduate Institute of Medical Sciences, Taipei Medical University, 6) Department of Pathology, Cathay General Hospital, 7) Graduate Institute of
Oncology, National Taiwan University and 8) Department of Obstetrics and Gynecology, College of Medicine, National Taiwan University, Taipei, Taiwan
Abstract
The present study aimed to evaluate a novel ﬂuorescence in situ hybridization (FISH) assay for detecting the high-risk human papilloma-
virus (HR-HPV) DNA and signal pattern in cervical cytology specimens and for identifying cervical intraepithelial neoplasia (CIN) lesions.
One hundred and ninety-six liquid-based cytology specimens with CIN were recruited. The signal pattern (punctate, mixed punctate
and diffuse, and diffuse) detected by FISH was compared with E6 mRNA and correlated with histological classiﬁcation. FISH and E6-type
speciﬁc polymerase chain reaction (PCR) had fair to good agreement for detecting HPV DNA across all grades of CIN (kappa coefﬁ-
cient, 0.37–0.73). Among 44 samples of negative FISH and positive E6 type-speciﬁc PCR in HPV 16, 18, 31, 33, 52 and 58, 82% (36/44)
of E6 mRNA were not detected, in contrast to 41% (48/118) of positive FISH and positive E6 type-speciﬁc PCR (p <0.0001). Among
HR-HPV DNA positive cases tested by the FISH assay, the speciﬁcity of predicting CIN3 using the punctuate pattern is higher than that
using E6 mRNA (96.3% vs. 44.8%). The punctate pattern was 0% in patients with <CIN1 lesions, 8.7% for CIN1 lesions, 6.1% for CIN2
lesions, and 34.0% for CIN3 lesions (p 0.001). The odds ratios were 8.7-fold higher (2.7–27.8, p <0.0001) for the punctate pattern
versus the mixed punctate and diffuse pattern, and the diffuse pattern, for predicting CIN3 lesions. The novel FISH assay is comparable
to PCR for detecting HPV DNA in cervical cytology with CIN lesions. The punctate signal pattern detected by the FISH assay can be
more biologically and clinically relevant for clinically detecting CIN3 lesions.
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Introduction
Cervical cancer is a major health burden in women. A total
of 493 000 women were diagnosed with cervical cancer and
273 000 died around the world in the year 2002. World-
wide, cervical cancer is the second most common female
cancer in the world, with a mean age standardized incidence
rate of up to 18.8 per 100 000 women, and it is a major
cause of mortality for women in developing countries
[1]. Persistent infections with high-risk types of human
papillomavirus (HR-HPV) represent a necessary cause of
cervical cancer [1–4]. HR-HPV DNA can be detected in up
to 99.7% of cervical squamous cell carcinomas [2,4] and in
94–100% of cervical adenocarcinomas and adenosquamous
carcinomas [5].
HPV is a common virus infection among women, particu-
larly in younger age groups, and most infections are transient
and asymptomatic. Patients with persistent infection with
these HPV types have a clearly enhanced risk of developing
cervical carcinoma [6]. Large-scale screening studies have
shown that HPV testing is more sensitive than a cytology
method for the detection of high-grade cervical lesions [6].
However, the low speciﬁcity of current assays and commer-
cial kits hampers the use of HPV testing in screening.
Although the combination of HPV DNA detection and
cytology is more suitable for risk assessment of the progres-
sion to cervical intraepithelial neoplasia (CIN) grade 3 and
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carcinoma than cytology alone [7], the false positive rate of
the HPV DNA test and the psychological burden for women
with HPV DNA positive is still high, and needs to be
improved. Hence, the detection of the signal pattern of HPV
DNA of high-risk HPV types using the ﬂuorescence in situ
hybridization (FISH) method would be attractive and might
serve as a better risk evaluation factor than the DNA test
for the detection of the development of CIN3.
One limitation of using in situ hybridization for HPV detec-
tion is its low sensitivity, with a detection limit was approxi-
mately 50 viral copies per cell. We developed a novel
method for detecting HPV DNA and signal pattern in one
procedure by FISH. In the present study, we tested the per-
formance of our novel FISH assay to determine the effective-
ness of the FISH assay for detecting HR-HPV in thin-layer
cervical specimens. In addition, the signal pattern (punctate,
mixed punctate and diffuse, and diffuse) detected by FISH
was compared with E6 mRNA and correlated with different
grades of cervical lesions. Using this novel FISH assays, we
address an important issue with respect to using the signal
pattern in high-risk HPV type detection for determining the
status of CIN3 in women and identifying a more biologically
and clinically relevant testing method.
Materials and Methods
Study design and population
This was a cross-sectional study conducted in 2005. The
study protocol was reviewed and approved by the Institu-
tional Review Board of Cathay General Hospital. All of the
participants provided their written informed consent before
being enrolled in the study. A total of 196 liquid-based cervi-
cal swabs were collected from 58 women with cytological
low-grade squamous intraepithelial lesions (LSIL) and 138
women with cytological high-grade squamous intraepithelial
lesions (HSIL). All of these 196 patients were examined by
colposcopy and the diagnosis was conﬁrmed by biopsy or a
loop electrosurgical excision procedure/cone. Each case was
ascertained by histological diagnosis based on the most
severe histology by biopsy or a loop electrosurgical excision
procedure/cone. Thus, we obtained specimens from 196
women: 29 women with <CIN1 lesions (abnormal cytology,
biopsy negative), 34 women with CIN1 lesions, 44 women
with CIN2 lesions, and 89 women with CIN3 lesions. Speci-
mens were tested for HPV DNA genotyping using a modi-
ﬁed MY11/GP6+ polymerase chain reaction (PCR) for HPV
DNA ampliﬁcation, followed by HPV genotype-speciﬁc
hybridization on a genechip. An E6 type-speciﬁc PCR was
performed to validate multiple infections. A total of 196
specimens including 165 positive HPV DNA tests in types
16, 18, 52, 58, 31, 33, 39, 45, 51, 56, 59, 68, 6 and 11, and
31 with negative HPV DNA detected by E6 type-speciﬁc
PCR, were examined by FISH. Among the 165 samples with
positive E6 type-speciﬁc PCR, 162 samples were positive in
HPV 16, 18, 52, 58, 31 and 33. Among the 162 samples, 118
samples had positive FISH with positive E6 type-speciﬁc
PCR, and 44 samples of negative FISH, but with positive E6
type-speciﬁc PCR, in HPV 16, 18, 31, 33, 52 and 58,
were examined by quantitative reverse-transcriptase PCR
(QRT-PCR). The signal patterns detected by FISH were
deﬁned as punctate, mixed punctuate and diffuse, and diffuse
patterns, and further correlated with different histopatholo-
gies of cervical lesions.
Collection of sample material
The cervical swabs were collected with a cytobrush by study
physicians, during routine and abnormal Pap smear ofﬁce vis-
its, and put into 20 mL of thinprep collection media, and
then stored at room temperature, no more than 2 weeks
before the allotment of samples was made.
Allotment of samples. After sample collection, two 2 mL aliqu-
ots of the liquid based cytology (PreservCyt; Cytyc Corpo-
ration, Malborough. MA, USA) sample were removed.
Samples were spun for 10 min at 2800 g. Subsequently, all
traces of PreservCyt medium were removed and the pel-
lets were store at )70C for DNA and RNA extraction.
One 10-mL aliquot of the liquid-based cytology sample was
removed for preparation of thin-layer slides within 2 weeks.
Residues materials were stored as pellets at )70C.
Control cell lines. CaSki cells (contains 60–600 HPV 16 DNA
copies per cell), HeLa cells (contains 10–50 HPV 18 DNA
copies per cell) and Jurkat cells (HPV-negative) were used
simultaneously to assess the entire procedures inclusive of
DNA extraction, RNA extraction, PCR HPV typing and FISH.
Control cells were suspended for 48 h in 20 mL of the same
preservation ﬂuid used for collecting cervical samples and
further processed as described for cervical smears.
Extraction of DNA. One aliquot of pellet material was for
DNA extraction via the QIAamp DNA Blood Mini kit (Qia-
gen Inc.,Valencia, CA, USA) in accordance with the manufac-
turer’s instructions. Extracted DNA was eluted in 100 lL AE
buffer (10 mM Tris, pH 8.5). DNA was stored at )20C until
analysis. The concentration of DNA extract was quantitated
by the Quant-iT PicoGreen reagent (Invitrogen Corp.,
Carlsbad, CA, USA) in accordance with the manufacturer’s
instructions.
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Extraction of RNA. One aliquot of pellet material was for
RNA extraction via the RNeasy Mini kit (Qiagen Inc.) in
accordance with the manufacturer’s instructions. The resid-
ual DNA was removed by optional DNase digestion using
the RNase-Free DNase Set (Qiagen Inc.). The DNase is efﬁ-
ciently removed in the subsequent wash steps. Extracted
RNA was eluted with 100 lL of RNase-Free Water. RNA
was stored at )70C until analysis. The concentration of
RNA extract was quantitated by the Quant-iT Ribo-
Green RNA assay kit (Invitrogen Corp.) in accordance
with the manufacturer’s instructions.
HPV genotyping by EasyChip HPV blot
HPV genotyping of the specimen DNA was carried out by
using a commercial EasyChip HPV blot kit (King Car, Tai-
pei, Taiwan) as described previously [9]. Brieﬂy, PCRs were
performed by using a modiﬁed MY11/GP6+ biotinylated
consensus primer set and a GAPDHF/GAPDHR biotinylated
primer set for ampliﬁcation of HPV and GAPDH, respec-
tively. The integrity of the PCR was conﬁrmed by gel elec-
trophoresis. The MY11/GP6+ primer set was used to
amplify a fragment of approximately 192 bp in the L1 open
reading frame of the HPV. The quality of specimen DNA
was validated by ampliﬁcation of a 136-bp fragment of GAP-
DH. All PCR reactions were performed by using a Gene-
Amp PCR System 9700 (Applied Biosystems, Foster City,
CA, USA).
The blot contains 39 type-speciﬁc probes, HPV 6, 11, 16,
18, 26, 31, 32, 33, 35, 37, 39, 42, 43, 44, 45, 51, 52, 53, 54,
55, 56, 58, 59, 61, 62, 66, 67, 68, 69, 70, 72, 74, 82, CP8061,
CP8304, L1AE5, MM4, MM7 and MM8, as well as three
intrinsic controls. The HPV type-speciﬁc probes are immobi-
lized on a 4.4 · 9.6 mm nylon membrane, which is used for
reverse-blot hybridization and detects HPV DNA in a single
assay. The HPV types displayed on the blot were determined
by using a standard visual assessment protocol.
HPV E6 type-speciﬁc PCR
The HPV E6 type-speciﬁc primer sequences and annealing
temperatures for the fourteen HPV genotypes are listed in
Table 1. The fourteen type-speciﬁc PCRs were performed in
parallel for each sample. For HPV E6 type-speciﬁc PCR analy-
sis, a control panel containing fourteen plasmid clones was
utilized as a positive control. Approximately 3800 bp of the
E6/E7/E1/E2 regions of HPV 6,11,16,18,31,33,39,45,51,52,
56,58,59 and 68 genomes from clinical samples were sepa-
rately cloned into pGEM T-Easy vector (Promega, Madison,
WI, USA) and sequenced for veriﬁcation of the genotypes.
TABLE 1. Primer sequences of the
14 type-speciﬁc E6 polymerase
chain reaction
Name Sequence Tm (C) Amplicon (bp)
16E6-F
16E6-R
GAGCGACCCAGAAAGTTACCAC
ACCTCACGTCGCAGTAACTGTTG
60 107
18E6-F
18E6-R
CGGCGACCCTACAAGCTACC
ACCTCTGTAAGTTCCAATACTGTCTTGC
60 107
31E6-F
31E6-R
GAAAGACCTCGGAAATTGCATGA
CTCTGTTTCTGTTAACTGACCTTTGCAGT
60 105
33E6-F
33E6-R
GAAAAACCACGAACATTGCATGA
ACCTCAGATCGTTGCAAAGGTTT
60 107
39E6-F
39E6-R
AATTGCCAGACCTGTGCACAA
CACTAAATGCAAATTCATATACCTCGGT
60 114
45E6-F
45E6-R
CAAGCTACCAGATTTGTGCACAGAA
AAAGCAAATTGATATACCTCTGTGCGT
60 111
51E6-F
51E6-R
CCACGAACGCTGCATGAATTAT
CAGTAAATGCTACATTATATACATCTGCTCTACA
60 121
52E6-F
52E6-R
ACACGACCCCGGACCCT
CTTGTATACCTCTCTTCGTTGTAGCTCTTT
60 114
56E6-F
56E6-R
CCACAGGAACGTCCACGAAG
CAAAATTATATACCTCAGCACGTGTTAGTTC
60 124
58E6-F
58E6-R
CCACGGACATTGCATGATTTG
GTCATATACCTCAGATCGCTGCAAA
60 106
59E6-F
59E6-R
CCTCTGCATGATATTCGCATCAA
CGCTGCATACGGTGTACAGTCTCT
60 123
68E6-F
68E6-R
CTGCCTATGTGGGTATTACACAGTTTTG
TGGCAGCACGGTGTGATACC
60 116
6E6-F
6E6-R
CTATCTATGCATACGTTGCAAATTAATTGT
CAGGACCTTTAGCTGTTTATATGCATATGA
60 99
11E6-F
11E6-R
GCACACTCTGCAAATTCAGTGCG
CACACAACCTTTAGGTTCTTATAGGCATATG
60 90
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All fourteen E6 type-speciﬁc primer pairs have been checked
by a chessboard test to conﬁrm their speciﬁcity (data not
shown). DNA ampliﬁcations were carried out in a 96-well
reaction plate format in an ABI Prism 5700 Sequence
Detection System (Applied Biosystems) and the speciﬁcity
was veriﬁed by dissociation curve. The reaction was
performed in a 25-lL mixture containing 1 · reaction Buffer
(HP HotStart Taq SYBR Green Kit; Protech, Tapei,
Taiwain) and 100 nM of primers. A 2.5-lL aliquot of DNA
extract was added to the reaction mixture. The ampliﬁcation
conditions were: 10 min at 95C, a two step cycle at 95C
for 10 s and 60C for 1 min for a total of 45 cycles. A
negative control for type-speciﬁc PCR (no DNA added to
the PCR cocktail) was included in each assay.
QRT-PCR for HPV E6 mRNA
The in vitro transcribed full-length E6/E7 mRNA was used as
quantitative standards for HPV 16, 18, 52, 58, 31 and 33 E6
mRNA analyses. A serial dilution of 10–10 000 000 copies
per lL of the artiﬁcial transcripts was used for analysis. The
analytical sensitivity was ten copies per lL of artiﬁcial tran-
scripts.
A two-step QRT-PCR was performed. First, for cDNA
synthesis, one 2.5-lL aliquot of template (RNA extract or in
vitro transcribed E6/E7 mRNA dilutions) was added to a
reagent mixture containing 10 pmol of HPV E6 reverse pri-
mer (as shown in Table 1), 3.75 U of reverse transcriptase
(Thermoscript, Invitrogen Corp.), 10 U of RNasin Plus
RNase Inhibitor (Promega), 5 nmol each of the deoxy-
nucleoside triphosphates (dGTP, dATP, dTTP and dCTP),
1 · cDNA Synthesis Buffer [50 mM Tris acetate (pH 8.4),
75 mM potassium acetate, 8 mM magnesium acetate] and
5 mM dithithreitol in a total volume of 10 lL. Negative
water blank was included in every analysis. The mixture was
incubated at 65C for 5 min and then at 60C for 30 min. A
reverse primer target to human GAPDH gene (GenBank
J04038) was also applied for all sample RNAs to validate the
quality of RNA extract. The GAPDH mRNA amplicon target
starts at base 1457 of the genomic sequence, spans two
introns, and ends at base 3412. The mRNA amplicon size is
226 bp. Second, one 2.5-lL aliquot of cDNA was added to
25 lL mixture containing 1 · reaction Buffer (HP HotStart
Taq SYBR Green kit; Protech) and 100 nM of primers for E6
regions or human GAPDH gene transcript for DNA amplica-
tion carried out in a 96-well reaction plate format in an ABI
Prism 5700 Sequence Detection System (Applied Biosys-
tems). The reactions were carried out in triplicate. The
ampliﬁcation conditions were 10 min at 95C, a two-step
cycle at 95C for 10 s, and 60C for 1 min for a total of 45
cycles. The speciﬁcity was veriﬁed by dissociation curve. All
sample RNAs were tested free of DNA contamination by
QRT-PCR without reverse transcriptase. Blank water was
included as a negative control in every analysis. Concentra-
tions of HPV mRNA were expressed as copies of HPV tran-
script in 50 ng of total mRNA. The negative or undetectable
HPV mRNA was deﬁned as <10 copies/lL or 100 copies/
50 ng total RNA. The details of primer sequences are shown
in Table 2.
FISH
Preparation of thin-layer slides. Thin-layer slides of cervical
smears were prepared using the SurePrep system (TriPath
Imaging, Burlington, NC, USA) in accordance with the manu-
facturer’s instructions, except for replacement of the preser-
vative ﬂuid by PreservCyt medium, and a novel apparatus
was utilized to prepare the thin-layer slides (patent pending).
The present invention aims to provide an apparatus for
preparation of three copies of thin-layer cell smear (with the
diameter of 12 mL) of one specimen on one slide to simplify
the thin-layer cell smear preparation and operations for the
in situ hybridization experiment by integrating two functions
in one apparatus.
TABLE 2. Primer sequences of
human papillomavirus 16, 18, 31,
33, 52 and 58 mRNA
Name Sequence Length Position Amplicon
16E6-F
16E6-R
GAGCGACCCAGAAAGTTACCAC
ACCTCACGTCGCAGTAACTGTTG
22
23
122–143
228–206
107
18E6-F
18E6-R
CGGCGACCCTACAAGCTACC
ACCTCTGTAAGTTCCAATACTGTCTTGC
20
28
129–148
235–208
107
31E6-F
31E6-R
GAAAGACCTCGGAAATTGCATGA
CTCTGTTTCTGTTAACTGACCTTTGCAGT
23
29
126–148
230–202
105
33E6-F
33E6-R
GTGCCAAGCATTGGAGACAACTATA
CATATACCTCAGATCGTTGCAAAGGT
25
26
153–177
238–213
86
52E6-F
52E6-R
ACACGACCCCGGACCCT
CTTGTATACCTCTCTTCGTTGTAGCTCTTT
17
30
120–136
233–204
114
58E6-F
58E6-R
CCACGGACATTGCATGATTTG
GTCATATACCTCAGATCGCTGCAAA
21
25
134–154
239–216
106
CMI Ho et al. Signal pattern of HPV in in situ hybridization 389
ª2010 The Authors
Clinical Microbiology and Infection ª2010 European Society of Clinical Microbiology and Infectious Diseases, CMI, 17, 386–394
Control cell lines. Human cervical cancer cell lines CaSki and
HeLa were served as intra- and inter-assay controls. In addi-
tion, a control panel consisted of fourteen transfected insect
cell lines was utilized to evaluate the speciﬁcity of the probe
sets. In brief, approximately 2500 bp length of the E6/E7/E1
regions of HPV 6, 11, 16, 18, 31, 33, 39, 45, 51, 52, 56, 58,
59 and 68 genomes were separately cloned into pIB/V5-His-
TOPO expression vector (Invitrogen Corp.). The High
Five cells (Invitrogen Corp.) were transfected with the
cloned expression vector in accordance with the manufac-
turer’s instructions. The stable cell lines were created by
multiple copy integration of the vector. Cells were sus-
pended for 48 h in 10 mL of the same preservation ﬂuid
used for collecting cervical samples and further processed as
described for cervical smears.
FISH probes. Fourteen HPV type-speciﬁc probes were sepa-
rately labelled by nick-translation of the 2500-bp fragments
of HPV E6/E7/E1 region with biotin-11-dUTP or DNP-11-
dUTP (Perkin-Elmer Life and Analytical Sciences, Shelton,
CT, USA) in accordance with the manufacturer’s instruc-
tions. All fourteen HPV type-speciﬁc probes have been
applied to the control panel for a chessboard test to con-
ﬁrm their speciﬁcity (data not shown). Three probe sets
were applied to one individual thin-layer slide at the same
time at a concentration of 1 ng/uL in 60% formamide,
2 · SSC, 10% dextran sulfate and 50· excess of carrier
DNA (salmon sperm DNA) and sealed with cover slide.
Set 1 consisted of biotin-labelled HPV 16 and DNP-labelled
HPV 18 probes. Set 2 consisted of biotin-labelled HPV 31/
33/39/45 and DNP-labelled HPV 6/11 probes. Set 3 con-
sisted of biotin-labelled HPV 52/58 and DNP-labelled HPV
51/56/59/68 probes.
Operation of FISH. Protein digestion of the cell smears was
carried out with 200 mg/L proteinase K (Amresco Inc.,
Solon, OH, USA) in phosphate-buffered saline for 20 min at
37C. For HPV typing, probe and target DNA were dena-
tured simultaneously for 5 min at 95C prior to hybridization
overnight at 37C. Post-hybridization washes were carried
out for 5 min at 25C in 2 · SSC/0.05% Tween 20 (pH 7.0),
then for 10 min at 60C in 0.1 · SSC/0.05% Tween 20 (pH
7.0). The slides were rinsed in TBS/0.05% Tween20 (TBST)
and detected by the following procedures.
The biotin-labelled probes were detected with sequential
incubation with Texas Red conjugated streptavidin (dilution
1:500; Invitrogen Corp.), biotinylated goat anti-streptavidin
(dilution 1:500; Vector Laboratories Inc., Burlingame, CA,
USA) and Texas Red conjugated streptavidin (dilution
1:500), all for 20 min at 25C, diluted and washed in TBST.
The DNP-labelled probes were detected with sequential
incubation with ﬂuoroscein isothiocyanate (FITC) conjugated
rabbit anti-DNP (dilution 1:500; Invitrogen Corp.), FITC
conjugated chicken anti-rabbit IgG (dilution 1:500; Invitrogen
Corporation) and FITC conjugated goat anti-chicken IgG
(dilution 1:500; Invitrogen Corp.), all for 20 min at 25C,
diluted and washed in TBST. After detection, the slides
were counterstained with 200 ng/mL 4¢,6-diamidino-2-
phenylindole (DAPI; Sigma Chemical Co., St Louis, MO,
USA), rinsed, air-dried and mounted in Fluorescence
Mounting Medium (DakoCytomation Denmark A/S, Glost-
rup, Denmark).
Analysis. The minimum cellularity of 5000 cells for each copy
of cell smear was examined and this threshold was based on
preliminary scientiﬁc evidence for liquid-based preparation
cell smears [8]. Images were recorded with SPOT RT-KE
Color 3-Shot CCD camera (Diagnostic Instruments Inc.,
Sterling Heights, MI, USA) mounted on a Nikon E800 ﬂuo-
rescence microscope (Nikon, Tokyo, Japan) equipped with
FITC, Texas Red and DAPI single bandpass ﬁlters for single
colour analysis and a dual bandpass ﬁlter set (FITC and
Texas Red) for simultaneous dual-colour analysis.
The signal patterns of HPV in nucleus using FISH were
classiﬁed: a diffuse signal throughout the nucleus was consid-
ered as diffuse pattern, and a punctate or dot signal within
the cell nucleus was considered as punctuate pattern. Both
punctuate and diffuse signals seen in the nucleus was deﬁned
as a mixed form.
Statistical analysis
The utility of the method of FISH was described using the
sensitivity, speciﬁcity and agreement of the test and the asso-
ciation between E6 type-speciﬁc PCR. The sensitivity was
deﬁned as the probability of a FISH positive given an E6
type-speciﬁc PCR positive and the speciﬁcity was deﬁned as
the probability of a FISH negative given an E6 type-speciﬁc
PCR negative. The estimates of sensitivity, speciﬁcity and
agreement, along with the exact two-sided 95% Clopper–
Pearson conﬁdence intervals, were calculated overall. The
comparison of FISH and mRNA for positive specimens of
HPV 16, 18, 52, 58, 31 and 33 detected by E6 type-speciﬁc
PCR was tested by the chi-square test. The association
between different signal pattern in FISH ﬁndings and different
degrees of CIN lesions was tested by using Mantel–Haenszel
trend test with a modiﬁed ridit score. The Stuart–Maxwell
test was used for testing marginal homogeneity in square
tables with more than two categories. These statistical tests
were conducted in SAS statistical software (SAS Institute,
Cary, NC, USA).
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Results
A total of 196 cases with 178 positive and 18 negative HPV
cases detected using MY11/GP6+ consensus primer-mediated
PCR assay, followed by HPV genotyping using EasyChip HPV
blot, were tested by the FISH assay. Among 178 HPV DNA
positive cases, 125 showed positive results by the FISH assay,
whereas none of 18 negative HPV DNA cases showed a
positive result detected by the FISH assay. A 73.0% (143/
196) concordance rate between FISH and HPV blot was
observed for the detection of HR-HPV cases. A total 82 of
178 HPV blot positive cervical samples contained a single
HPV type (46.1%) and 96 samples contained multiple HPV
types (53.9%). E6 type-speciﬁc PCR was further performed
to validate multiple infections. A total of 196 cases with 165
positive and 31 negative HPV cases detected using E6 type-
speciﬁc PCR were further tested using FISH. Among 165
HPV DNA positive cases, 124 showed positive FISH results,
whereas 30 of 31 negative HPV DNA cases were not
detected by FISH either. A 78.6% (154/196) concordance
rate between FISH and E6 type-speciﬁc PCR was observed
for the detection of HR-HPV cases. We used E6 type-spe-
ciﬁc PCR results as a reference standard; the accuracy rate
of individual HPV 16, 18, 52 and 58, which were the most
prevalent HPV types for CINs in Asia, was 66.0%, 76.5%,
73.7% and 77.1%, respectively. The accuracy rates of HPV 31
and 33 were 60% and 31.6%, respectively. Only one of 147
(0.7%) typings for HR-HPV DNA found to be positive as
examined by E6 type-speciﬁc PCR was shown to be negative
by the FISH assay. The concordance rate of HPV 16, 18, 52,
58, 31 and 33, which were the most prevalent types in this
study population, detected by HPV blot and E6 type-speciﬁc
PCR was 97.6%, 99.1%, 98.2%, 98.1%, 99.7% and 99.6%,
respectively.
Agreement between FISH and E6 type-speciﬁc PCR
The agreement between FISH and E6 type-speciﬁc PCR
assays for detecting HPV DNA is shown in Table 3. The
FISH and PCR assays had moderate to good agreement
(kappa coefﬁcients of 0.53 and 0.73, respectively) for detect-
ing HPV DNA in CIN1 and CIN2 lesions, and a fair agree-
ment (kappa coefﬁcients of 0.40 and 0.37, respectively) in
<CIN1 or CIN3 lesions (shown in Table 3). The sensitivity
of predicting CIN3 using the FISH assay was lower than that
using E6-type speciﬁc PCR (59.6% vs. 97.8%); in contrast, the
speciﬁcity of predicting CIN3 using the FISH assay was higher
than that using E6-type speciﬁc PCR (32.7% vs. 17.8%).
Comparison of FISH and mRNA for positive specimens of
HPV 16, 18, 52, 58, 31 and 33 detected by E6 type-speciﬁc
PCR
Among the 165 samples of E6 type-speciﬁc PCR positive,
162 samples positive in HPV 16, 18, 52, 58, 31 and 33 were
further examined by QRT-PCR. The sensitivity and speciﬁcity
of the E6 mRNA assay to predict CIN3 lesion were 89.7%
(70/78) and 57.1% (48/84), respectively. Among the 162 case
of positive E6 type-speciﬁc PCR in HPV 16, 18, 52, 58, 31
and 33, 118 were positive in HPV 16, 18, 52, 58, 31 and 33
by FISH. Forty-one percent (48/118) of HPV 16, 18, 52, 58,
31 and 33 E6 mRNA was not detectable (<10 cp/uL or
100 cp/50 ng total RNA) but revealed both positive FISH
and E6 type-speciﬁc PCR results. By contrast, among 44 sam-
ples of negative FISH but positive E6 type-speciﬁc PCR in
HPV 16, 18, 52, 58, 31 and 33, 82% (36/44) of them did not
detect E6 mRNA expression (p <0.0001) .
Comparison of punctate pattern in FISH and E6 mRNA for
predicting CIN3 in positive specimens of HPV 16, 18, 52, 58,
31 and 33 detected by E6 type-speciﬁc PCR
The representative pictures of punctuate pattern of clinical
samples in diffuse, diffuse and punctate, and punctate pat-
terns are shown in Fig. 1. As shown in Table 3, the frequen-
cies of the signal pattern of HPV 16, 18, 52/58, 31/33/39/45,
and 51/56/59/68 DNA in women with <CIN1 (abnormal
cytology and no CIN lesion in histology), CIN1, CIN2 and
CIN3 lesions detected by FISH were statistically different (p
0.001, Mantel–Haenszel trend test with a modiﬁed ridit
score). The punctate pattern was 0% in <CIN1, 8.7% for
CIN1 lesions, 6.1% for CIN2 lesions and 34.0% for CIN3
lesions (p 0.001) (Table 4). In addition, among HR-HPV
DNA positive cases tested by the FISH assay, the speciﬁcity
TABLE 3. Agreement between ﬂuorescence in situ hybrid-
ization and E6 type-speciﬁc polymerase chain reaction
(PCR) to detect onogenic human papillomavirus DNA in
cervical intraepithelial neoplasias (CINs)
Diagnosis
and in situ
hybridization
result
Number of cases (%) examined
by E6 type-speciﬁc PCR
Kappa
coefﬁcientPositive (%) Negative (%)
<CIN1
Positive 15 (93.8) 1 (6.2) 0.40
Negative 7 (53.8) 6 (46.2)
CIN1
Positive 23 (100) 0 (0) 0.53
Negative 6 (54.5) 5 (45.5)
CIN2
Positive 33 (100) 0 (0) 0.73
Negative 4 (36.4) 7 (63.6)
CIN3
Positive 53 (100) 0 (0) 0.37
Negative 24 (66.7) 12 (33.3)
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of predicting CIN3 using the punctuate pattern is higher than
that using E6 mRNA (94.4% (68/72) vs. 44.8% (30/67)). The
odds ratio were 8.74-fold higher (2.75–27.82, p <0.0001) for
the punctate pattern versus the mixed punctate and diffuse
pattern, and the diffuse pattern, for predicting CIN3 lesions.
Discussion
Our survey is the ﬁrst study to address the use of a novel
FISH assay (non-tyramide labelling) for detecting both 12
HR-HPV DNA typing and signal pattern in thin-layer cervical
specimens. Because HPV blot could detect more HPV types
(39 types) than our FISH method, rationally, we used E6
type-speciﬁc PCR independently to detect 14 HPV types,
which included the detection of all types of FISH probes, as
a reference standard for HPV typing and to validate multiple
infections of cervical specimens.
Our novel FISH assay using three sets of probes, including
12 HR-HPV type 16, 18, 52/58, 31/33/39/45, 51/56/59/68,
and low-risk type 6/11, in one panel for HPV typing can
reach a speciﬁcity of 96.8% for specimens that were negative
for HR-HPV, and a speciﬁcity of 75.2% for the detection of
HR-HPV positive cases between FISH and E6 type-speciﬁc
PCR. Our FISH assays and E6-type speciﬁc PCR had fair to
good agreement for detecting HPV DNA across all grades of
CIN (kappa coefﬁcient, 0.37–0.73). Our results obtained in
liquid-based cytology specimens are consistent with a previ-
ous report by Guo et al. [9] using tissue specimens. When
we compared FISH and E6 mRNA in those samples of FISH
negative but E6 type-speciﬁc PCR positive in HPV 16, 18, 52,
58, 31 and 33, most (82%) were not expressed in E6 mRNA.
Our results demonstrate that our novel FISH assays may be
more biologically relevant for detecting CINs.
In situ hybridization approaches were reported to suffer
from low sensitivity, but PCR-based assays lead to a low
speciﬁcity and high false positive rate in the detection of
CIN lesions [10]. Previous studies compared hybrid capture
2 with in situ hybridization for the detection of HR-HPV in
liquid-based cervical samples, and reported inferior results
using in situ hybridization [10,11]. On the other hand,
another study compared the HC2 with a sensitive non-tyra-
mide-based chromogenic in situ hybridization method for the
analysis of liquid-based cervical samples with atypical squa-
mous cells of undetermined signiﬁcance (ASCUS) and LSIL,
and showed that HR-HPV testing by in situ hybridization is a
viable alternative to HC2 [12]. We ﬁrst evaluated whether
the sensitivity of our FISH assay is sufﬁcient to view HPV
and the signal pattern clearly in CaSki (60–600 DNA copies)
or HeLa (10–50 copies) cell lines. Our FISH assay did not
utilize a PCR reaction or tyramide signal ampliﬁcation system
to detect fewer HPV-infected cells presented in a thin-layer
cervical samples preparation because these two methods
were very sensitive in detecting few low-risk types of HPV-
infected cells. Meanwhile, 0.7% of false positive rate for
detecting HPV DNA allowed us to use the FISH assay to
accurately detect HPV without cross hybridization. Despite
labelling fewer samples as HPV DNA positive than E6
(b)
(c) (e)
(f)
(a)
(d)
FIG. 1. The representative pictures of
ﬂuorescence in situ hybridization assays.
(a) Diffuse pattern in HPV 16 infection.
(b) Diffuse pattern in HPV 58 infection.
(c) Mixed diffuse and punctuate pattern
in HPV 16 infection. (d) Mixed diffuse
and punctuate pattern in HPV 58 infec-
tion. (e) Punctate pattern in HPV 16
infection. (f) Punctuate pattern in HPV
58 infection.
TABLE 4. Signal pattern according to ﬂuorescence in situ
hybridization method stratiﬁed by cervical intraepithelial
neoplasia (CIN) <1, CIN1, CIN2 and CIN3 in human papillo-
mavirus 16, 18, 52/ 58, 31/33/39/45, 51/56/59/68 DNA posi-
tive specimens
<CIN1
n (% of total
number)
CIN1
n (%)
CIN2
n (%)
CIN3
n (%)
Punctate 0 (0.0) 2 (8.7) 2 (6.1) 18 (34.0)
Mixed 6 (37.5) 10 (43.5) 20 (60.6) 25 (47.2)
Diffuse 10 (62.5) 11 (47.8) 11 (33.3) 10 (18.8)
p <0.001 by Mantel–Haenszel trend test with a modiﬁed ridit score, n, patient
number.
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type-speciﬁc PCR, our FISH method can reduce the false
positive rate and achieve a high speciﬁcity for predicting
cervical disease progression. Additionally, it offers the
opportunity to view the signal pattern of HPV infection,
which permits a cytochromogenic link in the assessment of
disease severity.
Recently, the detection rate of HR-HPV has been increased
by using a HPV catalyzed receptor deposition (CARD) system
[13]. However, the false positive rate can be up to 21%. The
goal of our FISH efforts was to produce a reliable assay to
detect HR-HPV typing and signal pattern in one set, and
hopefully, be sensitive enough to detect a single HPV-infected
cell among thousands of cells in a thin-layer of cervical speci-
mens. HC2 assays are based on a target ampliﬁcation tech-
nique with subsequent hybridization, and HPV blots are based
on PCR-based approaches with subsequent hybridization.
Basically, these approaches demonstrate high sensitivity but
low speciﬁcity to detect CIN lesions. The probe mix in the
HPV-CARD assay was designed based on entire HPV DNA
sequences that were cloned into plasmid and included a
probe cocktail for HPV types 16, 18, 30, 45, 51 and 58, which
should hybridize to all HPV types sharing >50% sequence
homology with any of the six HPV types in the probe mix at
lower stringency hybridization conditions for detecting 12
high risk types. Without doubt, the cross hybridization is high
in HPV-CARD system. The probe mix in our assay were
designed based on HPV genome between E6–E7 and E1–E2
around 2500 bp, and the sequence homology between any of
the 12 HR-HPV types was lower than that of HPV-CARD.
Although the sensitivity for the detection of HR-HPV positive
cases was lower than that of HPV-CARD (75.2% vs.91%), the
false positive rate was much lower in our FISH assay (0.7% vs.
21%). In evaluating HPV signal patterns in CIN, the punctuate
pattern was found to be more frequent in CIN3, whereas a
mixed punctuate and diffuse pattern, and the diffuse pattern,
were predominantly observed in CIN1. Our ﬁndings were
consistent with those of previous studies [14–16]. We also
observed a good correlation between the punctuate signal
pattern and the severity of cervical dysplasia. The punctuate
pattern in FISH assay revealed an odds ratio of up to 8.7-fold
higher than the other two patterns in FISH assay for predict-
ing CIN3 lesions. Our novel FISH assay might miss a few
CIN3 cases. However, the FISH assay could save much unnec-
essary follow-up. Besides, Lie et al. [17], also suggested that
the RNA negative, DNA positive high-grade cases would be
more likely to regress without intervention. A prospective
study is needed to conﬁrm this point.
Integration is proposed to be an important step in the
progression of intraepithelial lesions of the cervix to invasive
cervical cancer. Hopman et al. [18] reported that integration
represents a marker for transition from high-grade CIN to
micro-invasive carcinoma, using tyramide-based in situ hybrid-
ization to detect HPV-16- or -18-positive CIN and micro-
invasive lesions. However, whether every punctate signal
observed in thin-layer cervical specimens represents integra-
tion is questionable. Recently, Algeciras-Schiminich et al. [13]
reported that the very sensitive tyramide ampliﬁcation sys-
tem assay (CARD) can detect only a few copies of HPV per
cell, as demonstrated by detection of integrated HPV in the
HeLa and SiHa cell lines. However, the sensitivity produced
by tyramide reagents may increase the risk of nonspeciﬁc
staining that resembles punctuate signals [19]. Theoretically,
a system capable of detecting single-copy integrated HPV is
also presumably able to detect single/low-copy episomal
HPV, which may give rise to an apparently punctate pattern.
Besides, HPV concatamers and/or high molecular weight epi-
somes that have undergone genetic rearrangement may be
common in high-grade CIN lesions and are difﬁcult to distin-
guish from integrated HPV [20]. Of note, 46% of HSIL and
34% in LSIL specimens were reported by Algeciras-Schimi-
nich et al. [13], which was much higher than the values of
34.0% for CIN3 and 8.7% for CIN1 in our study population
detected as a punctate signal pattern. It appears that punc-
tate signal pattern detected by our FISH assay is more spe-
ciﬁc than the CARD system, and potentially could be used a
biomarker to detect CIN3 in thin-layer cervical specimens.
In conclusion, we have developed a novel FISH assay to
detect HR-HPV type and signal pattern in the same liquid-
based cervical specimens in different grades of cervical
lesions. Our assay offered a high speciﬁcity and an acceptable
sensitivity for HR-HPV detection. The present study also
demonstrates a positive correlation between the punctuate
signal pattern and disease severity. The novel FISH assay can
be more biologically and clinically relevant for detecting
CIN3 lesions. A larger sample size and a comparison with
biopsy results is needed to further investigate the clinical
utility in liquid-based cytology specimens.
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